ISRG Related Analyst Ratings
-
Barrington Research Adds Intuitive Surgical (ISRG) to 'Best Ideas List'
-
Weakness in Intuitive Surgical (ISRG) is A Buying Opportunity - Goldman Sachs
-
WallachBeth Capital Starts Intuitive Surgical (ISRG) at Buy
-
Goldman Sachs Defends Intuitive Surgical (ISRG)
-
Canaccord Genuity Upgrades Intuitive Surgical (ISRG) to Buy
-
BAML: We're Surprised Intuitive (ISRG) Sold-Off on ACOG Post
-
Northland Securities Starts Intuitive Surgical (ISRG) at Underperform
-
Nothing Will Change for MAKO Surgical (MAKO) Amid Intuitive (ISRG) Probe
-
Intuitive Surgical (ISRG) Shares Surge Following Thursday Freak-out
-
Buy Intuitive Surgical (ISRG) 'Aggressively' Under $550, FDA Check-Up Sounds Routine
-
Cantor Fitzgerald Upgrades Intuitive Surgical (ISRG) to Buy; Sell-Off a 'Gross Overreaction'
-
Goldman Sachs Upgrades Intuitive Surgical (ISRG) to Buy, Sees 28% Upside
-
Canaccord Genuity Ups Intuitive Surgical (ISRG) PT to $590 on Solid Q4
-
Janney Montgomery Scott Starts Intuitive Surgical (ISRG) at Buy
-
Intuitive Surgical (ISRG) Remains Under Short Seller Attack, But a Product Refresh Could Provide Upside
-
Lazard Capital Upgrades Intuitive Surgical (ISRG) to Buy
-
Intuitive Surgical (ISRG) Still Mum on Citron Report, But Analysts Weigh-In
-
Bloom Could Come Off Intuitive Surgical's (ISRG) Rose as Lawsuits Fly - Citron
-
Cantor Fitzgerald Raises Numbers on Intuitive Surgical (ISRG)
-
Stifel Nicolaus Starts Intuitive Surgical (ISRG) at Hold
-
SunTrust Robinson Humphrey Starts Intuitive Surgical (ISRG) at Buy
-
Barrington Research Upgrades Intuitive Surgical (ISRG) to Outperform
-
BofA/Merrill Lynch Upgrades Intuitive Surgical (ISRG) to Buy
-
UPDATE: JPMorgan Upgrades Intuitive Surgical (ISRG) Saying LT Opportunities Outweigh NT Pressures
-
Mizuho Securities Upgrades Intuitive Surgical (ISRG) to Buy
-
Dougherty & Co Defends Intuitive Surgical (ISRG); Issues Well Known and Already Priced In
-
Cantor Fitzgerald on Intuitive Surgical (ISRG): Good Q2, But Shares Are Priced For Perfection
-
Leerink Swann Q2 Review on Intuitive Surgical (ISRG); Delivered Again; Raising Estimates and PT
-
Goldman Sachs Lifts Target on Intuitive Surgical (ISRG) Despite New Questions
-
Intuitive Surgical (ISRG) Shares Sell Off As Outlook Commentary is Meager
-
Needham & Company Maintains a 'Hold' on Intuitive Surgical (ISRG); This Isn't MAKO, But Macro Not Helpful
-
Q2 Kickoff: Alcoa (AA) Investors to Focus on LME Prices, Downstream Ops, and China
-
Raymond James Starts MedTech Sector: CFN, COO, COV at Strong Buy, SLTM, ISRG, BAX at Outperform, BDX at Underperform
-
Cantor Fitzgerald Maintains a 'Hold' on Intuitive Surgical (ISRG); Raising Numbers, But Not Looking To Chase Shares
-
Canaccord Genuity Maintains a 'Hold' on Intuitive Surgical (ISRG); Strong Q1 Expected; Shares Close to Fully Valued
-
Goldman Sachs Boosts Price Target on Intuitive Surgical (ISRG), But Keeps Neutral Rating
-
Canaccord Genuity Maintains a 'Hold' on Intuitive Surgical (ISRG); Q1 Should Beat, But Valuation Fully Accounts For Strong Growth
-
Dougherty & Co Starts Intuitive Surgical (ISRG) at Buy; Healthy Market for Da Vinci
-
Lazard Downgrades ISRG, AGN, ELGX, STJ, ZOLL to Neutral
-
Lazard Capital Boosts Price Target on Intuitive Surgical (ISRG) to $575
-
Analyst Says Japanese Reimbursement for Intuitive's (ISRG) da Vinci to Begin in April
-
Collins Stewart Raises Price Target on Intuitive Surgical (ISRG) Following Earnings
-
Goldman Sachs Keeps On the Sidelines With Intuitive Surgical (ISRG)
-
Canaccord Genuity Maintains a 'Hold' on Intuitive Surgical (ISRG); 2012 Sales Guidance A Bit Lower Than Expected
-
Q4 Preview: Seasonally-Strong Year-End Quarter Could Bode Well for Intuitive Surgical (ISRG)
-
ThinkEquity Starts Intuitive Surgical (ISRG) at Buy
-
Cantor Fitzgerald Starts Intuitive Surgical (ISRG) at Hold; High-Quality Growth, but Priced for Perfection
-
Canaccord Genuity Reiterates a 'Hold' on Intuitive Surgical (ISRG); Growth Train Keeps Chugging - Raising PT to $450
-
Goldman Sachs Raises Price Target On Intuitive Surgical (ISRG), Momentum Unlikely to Reverse
-
Collins Stewart Maintains a 'Buy' on Intuitive Surgical (NASDAQ: ISRG); Task Force Recommends Against PSA Screening - See Limited Fallout
Back to ISRG Stock Lookup
